Gastroenterology

Mallinckrodt completes phase 3 enrollment for hepatorenal syndrome drug



Mallinckrodt achieved target enrollment of 300 participants for a phase 3 clinical study designed to evaluate the safety and efficacy of terlipressin for patients with hepatorenal syndrome type 1, according to a press release.
“Currently, there are no treatments approved in the U.S. and Canada for the treatment of [hepatorenal syndrome type 1 (HRS-1)], which is a serious disease that has a high mortality rate,” Arun Sanyal, MD, lead investigator from the Virginia Commonwealth University, said in the release. “Reaching this critical milestone of full enrollment in the CONFIRM

Source link

Related posts

How to stimulate appetite

Newsemia

Study Pinpoints Factors Tied to Aggressive SCC After Transplant (CME/CE)

Newsemia

T2DM Increases Gastric Cancer Risk After H. Pylori Eradication

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World